A Phase I Study To Evaluate Psca-Targeting Chimeric Antigen Receptor (Car)-T Cells For Patients With Psca Plus Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Tanya B. Dorff,Suzette Blanchard, Patti Carruth,Jamie Wagner,Peter Kuhn,Ammar Chaudhry,Lauren Adkins,Sandra Thomas,Hripsime Martirosyan,Peiguo Chu,Sumanta K. Pal,Stephen J. Forman,Saul Priceman

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 8|浏览27

暂无评分

摘要

TPS250Background: Although treatment options have improved, mCRPC remains highly lethal. Immunotherapy holds potential for durable remissions but not yet in mCRPC. CAR-T cell therapy has yielded cu...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要